Stryker Corporation (NYSE:SYK – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the twenty-four research firms that are currently covering the firm, MarketBeat.com reports. Six research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $369.00.
Several equities analysts have weighed in on the company. BMO Capital Markets reaffirmed an “outperform” rating and issued a $317.00 target price on shares of Stryker in a research report on Wednesday, September 9th. Wells Fargo & Company cut their price target on shares of Stryker from $418.00 to $348.00 and set an “overweight” rating on the stock in a research note on Wednesday, September 9th. Sanford C. Bernstein reissued a “market perform” rating on shares of Stryker in a research report on Wednesday, October 7th. Raymond James Financial set a $370.00 price target on shares of Stryker in a research report on Friday, July 31st. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Stryker from $400.00 to $350.00 and set an “overweight” rating for the company in a research note on Friday, July 31st.
Get Our Latest Stock Report on SYK
Stryker Trading Down 0.3%
Stryker (NYSE:SYK – Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%. The firm had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. During the same quarter in the previous year, the business earned $3.13 EPS. The company’s quarterly revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, equities analysts expect that Stryker will post 14.95 earnings per share for the current year.
Stryker Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 1.2%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s dividend payout ratio is presently 36.48%.
Insiders Place Their Bets
In other Stryker news, Director Ronda E. Stryker sold 50,000 shares of the business’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $340.10, for a total value of $17,005,000.00. Following the completion of the transaction, the director owned 2,251,375 shares in the company, valued at $765,692,637.50. The trade was a 2.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Dylan Crotty sold 441 shares of the business’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $328.61, for a total transaction of $144,917.01. Following the completion of the transaction, the insider owned 6,102 shares of the company’s stock, valued at approximately $2,005,178.22. This trade represents a 6.74% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 351,267 shares of company stock worth $118,197,701 in the last ninety days. 4.60% of the stock is owned by corporate insiders.
Institutional Trading of Stryker
Several hedge funds have recently modified their holdings of SYK. Perpetual Ltd boosted its position in shares of Stryker by 17,298.2% during the 3rd quarter. Perpetual Ltd now owns 338,569 shares of the medical technology company’s stock worth $93,239,000 after acquiring an additional 336,623 shares in the last quarter. Rockland Trust Co. increased its holdings in shares of Stryker by 1.1% in the 3rd quarter. Rockland Trust Co. now owns 3,365 shares of the medical technology company’s stock valued at $927,000 after acquiring an additional 36 shares during the last quarter. Envestnet Portfolio Solutions Inc. raised its position in shares of Stryker by 22.5% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 10,436 shares of the medical technology company’s stock worth $3,286,000 after acquiring an additional 1,915 shares in the last quarter. Envestnet Asset Management Inc. raised its position in shares of Stryker by 12.2% during the 2nd quarter. Envestnet Asset Management Inc. now owns 650,461 shares of the medical technology company’s stock worth $204,790,000 after acquiring an additional 70,634 shares in the last quarter. Finally, State Street Corp raised its position in shares of Stryker by 1.2% during the 2nd quarter. State Street Corp now owns 15,532,565 shares of the medical technology company’s stock worth $4,903,772,000 after acquiring an additional 183,400 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.
Trending Headlines about Stryker
Here are the key news stories impacting Stryker this week:
- Positive Sentiment: Stryker received FDA 510(k) clearance for Sonopet 3, an ultrasonic tissue-removal system designed to provide greater power, precision and versatility in bone and soft-tissue procedures. The launch could support future revenue growth and strengthen Stryker’s surgical portfolio. Stryker launches Sonopet 3
- Positive Sentiment: Stryker is investing $400 million in CMR Surgical and obtaining exclusive U.S. sales rights for the Versius robotic-assisted surgery system, with an option to acquire the company. The deal expands Stryker into soft-tissue robotics and could create a new growth platform, although it also involves execution and investment risks. Stryker and CMR Surgical robotics deal
- Positive Sentiment: Leerink Partners maintained its Buy rating on SYK, suggesting the analyst remains constructive on the company’s operating outlook and long-term growth prospects. Leerink Partners maintains Buy rating
- Neutral Sentiment: Stryker is scheduled to report third-quarter results on October 29. Investors will focus on procedure volumes, organic sales growth, margins and whether the company remains on track for its fiscal 2026 EPS guidance of $14.95–$15.10. Stryker earnings preview
- Negative Sentiment: Law firms including Frank R. Cruz and Pomerantz announced investigations into potential violations of federal securities laws. The announcements do not establish wrongdoing, but they may increase legal uncertainty, reputational risk and volatility for SYK while investors await more details. Securities fraud investigation into Stryker
About Stryker
Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used in hospitals, surgical centers and other healthcare settings. Founded in 1941 by Dr. Homer Stryker in Kalamazoo, Michigan, the company has grown from an orthopedic device business into a diversified provider of medical technologies.
Stryker’s product portfolio includes orthopedic implants and instruments, surgical equipment, neurovascular devices, spine products, patient-handling and emergency-care equipment, operating-room systems, and digital and robotic technologies.
Featured Stories
- Five stocks we like better than Stryker
- Tesla Wants to Make Its Own Chips—What Could Go Wrong?
- IREN Limited’s AI Pivot Gains Traction—But Can Its Data Centers Deliver?
- PBF Energy’s Stunning Rally Faces a Critical Test
- Citi Stock Falls Despite Earnings Beat: What Investors Need to Know
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.
